In addition, some teams have also explored bispecific CAR-T, such as targeting both TIM-3 and CD13, which demonstrated higher tumor clearance and relatively controllable toxicity to normal hematopoietic stem cells in AML mouse models (43). This evidence concerns the gene HAVCR2 and acute myeloid leukemia.